ATEMPT 2.0: Adjuvant T-DM1 vs TH
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|HER2-positive Breast Cancer
Interventions: DRUG: trastuzumab-emtansine|DRUG: Trastuzumab SC|DRUG: Paclitaxel
Sponsor: Dana-Farber Cancer Institute
Collaborators: Genentech, Inc.